How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review

BACKGROUND: Despite the increasing economic assessment of biomarker-guided therapies, no clear agreement exists whether existing methods are sufficient or whether different methods might produce different cost-effectiveness results. This study aims to examine current practices of modeling companion...

Descripción completa

Detalles Bibliográficos
Autores principales: Seo, Mikyung Kelly, Cairns, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408935/
https://www.ncbi.nlm.nih.gov/pubmed/34470603
http://dx.doi.org/10.1186/s12885-021-08725-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408935/
https://www.ncbi.nlm.nih.gov/pubmed/34470603
http://dx.doi.org/10.1186/s12885-021-08725-4

Ejemplares similares